10-K: Evofem Biosciences Reports 2023 Financial Results Amidst Merger Agreement with Aditxt

Sentiment:

Annual Report 27 March 2024 8:40 AM

📋All filings for Evofem Biosciences, INC

Evofem Biosciences reports its 2023 financial results, highlighting a revenue increase despite reduced unit sales, while also navigating a merger agreement with Aditxt.

Delay expectedThe Merger is expected to be closed in the second half of 2024, which is a delay from the original expected closing date.

Capital raiseThe company must raise significant additional funds to finance its operations and to remain a going concern.The company may not be able to raise additional capital when needed or on acceptable terms.

Worse than expectedThe company's independent auditors have included a going concern explanatory paragraph in their report on the consolidated financial statements.The company has a working capital deficit of $63.3 million and an accumulated deficit of $888.7 million as of December 31, 2023.The company is currently over 90 days past due on a significant amount of vendor obligations, with approximately $15.6 million past due.

Summary

Evofem Biosciences, a commercial-stage biopharmaceutical company focused on women's health, released its 2023 financial results.
Net product sales increased by 8% compared to 2022, reaching $18.2 million, despite a 12% decrease in unit shipments.
The company experienced a significant decrease in research and development expenses, down 88% to $2.9 million, due to the halt of clinical development programs.
Selling and marketing expenses also saw a substantial reduction, decreasing by 73% to $11.7 million.
General and administrative expenses decreased by 46% to $15.0 million.
The company reported a net income of $53.0 million, primarily due to a non-cash gain on debt extinguishment.
The company has a working capital deficit of $63.3 million and an accumulated deficit of $888.7 million as of December 31, 2023.
The company is currently over 90 days past due on a significant amount of vendor obligations, with approximately $15.6 million past due.
The company is in the process of a merger with Aditxt, Inc., expected to close in the second half of 2024.
The company's independent auditors have included a going concern explanatory paragraph in their report on the consolidated financial statements.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive revenue growth but significant financial challenges, including a going concern warning and substantial debt. The merger agreement introduces uncertainty, and the company's reliance on external funding and third parties adds to the risk. Overall, the sentiment is negative due to the financial instability and operational challenges.

Positives

Net product sales increased by 8% compared to 2022, reaching $18.2 million.
The company reported a net income of $53.0 million, primarily due to a non-cash gain on debt extinguishment.
The company has secured 73% coverage within its Commercial and Medicaid books of business, including 19.8 million lives covered at no out-of-pocket cost.
Phexxi co-pay card utilization has decreased 47% since January 1, 2023, while claims have remained stable.

Negatives

The company experienced a 12% decrease in unit shipments compared to 2022.
The company has a working capital deficit of $63.3 million and an accumulated deficit of $888.7 million as of December 31, 2023.
The company is currently over 90 days past due on a significant amount of vendor obligations, with approximately $15.6 million past due.
The company's independent auditors have included a going concern explanatory paragraph in their report on the consolidated financial statements.

Risks

The company is currently over 90 days past due on a significant amount of vendor obligations.
The company may not be able to refinance, extend or repay its substantial indebtedness owed to its secured and unsecured lenders.
The company has incurred significant losses and negative cash flows since its inception and anticipates it will continue to incur significant losses and negative cash flow for the foreseeable future.
The company must raise significant additional funds to finance its operations and to remain a going concern.
Failure to complete the merger with Aditxt could negatively impact the company's stock price and future business.
The company may be subject to litigation relating to the Merger.
The company is subject to risks and uncertainties associated with potential bankruptcy proceedings.
The company faces competition from other medical device, biotechnology, and biopharmaceutical companies.
The company may fail to receive approval to market Phexxi outside the US.
The company has not paid its Fiscal Years 2023 or 2024 PDUFA Invoice for Phexxi to the FDA.
Product liability lawsuits against the company could cause it to incur substantial liabilities and limit commercialization of Phexxi.
The company's rights to develop and commercialize Phexxi are subject, in part, to the terms and conditions of licenses granted to it by third parties.
The company's success relies on third-party suppliers and one contract manufacturer.
Changes in health care laws and regulations may eliminate current requirements for health insurance plans to cover and reimburse FDA-cleared or FDA-approved contraceptive products without cost sharing.
The company's stock price is and may continue to be volatile.
There may not be an active, liquid trading market for the company's equity securities.
The company's common stock could be further diluted as the result of the issuance of additional shares of common stock, convertible securities, warrants or options.
The company is and may continue to be subject to short-selling strategies.
The company's business could be negatively affected as a result of the actions of activist stockholders.
The company may become a defendant in one or more stockholder derivative or class-action litigation(s).

Future Outlook

The company expects to continue to focus on top-line growth and maintain a lean operating structure in 2024, while also exploring opportunities for organic growth, entry into new markets, and expansion of its product offering beyond Phexxi. The merger with Aditxt is expected to close in the second half of 2024.

Management Comments

Management believes that the Companys cash and cash equivalents as of December 31, 2023 are insufficient to fund operations for at least the next 12 months from the filing date of March 27, 2024.
Management plans to meet the Companys cash flow needs in the next 12 months include generating revenue from the sale of Phexxi and additional products, further restructuring of its current payables, and obtaining additional funding through means such as the issuance of its capital stock, non-dilutive financings, or through collaborations or partnerships with other companies, including license agreements for Phexxi in the US or foreign markets, or other potential business combinations (including the Merger).

Industry Context

The document highlights the competitive landscape of the contraceptive market, noting the presence of established pharmaceutical companies and generic manufacturers. It also emphasizes the growing demand for non-hormonal birth control methods, which presents an opportunity for Phexxi.

Comparison to Industry Standards

The document notes that the US contraceptive market is valued at $8.7 billion in 2023 and is expected to reach approximately $12 billion by 2030, with a compound annual growth rate of 4.7%.
The document also mentions that global sales of non-hormonal contraceptives are forecasted to increase from $27.7 billion in 2022 to $52.2 billion by 2031.
The document compares Phexxi to other contraceptive options, including hormonal birth control pills, patches, rings, IUDs, implants, injectables, and OTC methods like condoms and spermicides.
The document notes that the only non-hormonal option within the top five sales-generating segments in 2022 was the male condom, which is an over-the-counter (OTC) product.
The document also notes that an estimated 257 million women who want to avoid pregnancy are not using safe, modern methods of contraception and nearly half of all pregnancies 121 million each year are unintended according to the United Nations 2022 State of World Population 2022 report.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	Justin J. File	Ivy Zhang	April 13, 2023	Resignation of previous CFO
Chief Commercial Officer	Katherine Atkinson		March 17, 2023	Elimination of the role as part of a Reduction in Workforce

Legal Proceedings

The company was involved in a trademark dispute with TherapeuticsMD, Inc., which was settled in July 2022.
The company filed a complaint for patent infringement against Padagis Israel Pharmaceuticals Inc. in June 2023, which was subsequently dismissed in September 2023.

Stakeholder Impact

Shareholders face the risk of further dilution and potential loss of investment due to the company's financial instability and need for additional capital.
Employees may experience job insecurity due to the company's cost-cutting measures and potential bankruptcy proceedings.
Customers may face uncertainty regarding the availability and pricing of Phexxi due to the company's financial challenges and potential changes in ownership.
Suppliers and creditors face the risk of non-payment or delayed payments due to the company's financial difficulties.

Next Steps

The company will continue to focus on top-line growth and maintain a lean operating structure.
The company will explore opportunities for organic growth, entry into new markets, and expansion of its product offering beyond Phexxi.
The company will work to close the merger with Aditxt, Inc. in the second half of 2024.

Key Dates

Date	Description
2020-04-23	Date of the original Securities Purchase and Security Agreement with Baker Bros.
2020-05-22	Phexxi was approved by the FDA.
2020-09-08	Phexxi was commercially launched in the US.
2021-10-12	Date of the initial closing of a registered direct offering with Keystone Capital Partners.
2021-10-26	Date of the additional closing of the registered direct offering with Keystone Capital Partners.
2022-03-24	Date of the exchange agreement with the holder of Series B-2 Convertible Preferred Stock.
2022-05-04	Date of the exchange agreement with the May 2022 Notes Purchasers.
2022-05-18	Date of the reverse stock split.
2022-07-18	Date of settlement of the trademark dispute with TherapeuticsMD, Inc.
2022-09-15	Date of the Third Amendment to the Baker Bros. Purchase Agreement and the Adjuvant Forbearance Agreement.
2022-10-26	Date of delisting from the Nasdaq Capital Market.
2022-12-16	Date of filing of the Certificate of Designation of Series D Non-Convertible Preferred Stock.
2023-03-07	Date of the Notice of Event of Default and Reservation of Rights from Baker Bros.
2023-08-07	Date of filing of the Certificate of Designation of Series E-1 Convertible Preferred Stock.
2023-09-08	Date of the Fourth Amendment to the Baker Bros. Purchase Agreement.
2023-12-11	Date of the Merger Agreement with Aditxt, Inc.
2023-12-21	Date of the exchange of warrants for Series F-1 Shares.
2024-02-26	Date of the Assignment Agreement with the Baker Purchasers.
2024-02-29	Date of the third amendment to the Merger Agreement.

Keywords

Evofem Biosciences, Phexxi, financial results, merger, Aditxt, women's health, contraception, biopharmaceutical, debt, revenue, clinical development, stock, OTCQB

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.